Skip to main content
. 2017 Feb 21;28(6):1339–1345. doi: 10.1093/annonc/mdx075

Figure 1.

Figure 1

CONSORT diagram. *Indicates two patients randomly assigned to receive sunitinib did not receive treatment. Indicates after first-line treatment discontinuation. Indicates ineligibility included poor performance status or decline in condition primarily related to progressive disease, brain metastases, or persistent adverse events. §Patients crossed over after the cutoff date. FAS, full analysis set.